# Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

> **NCT02928029** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 7 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)
- **DRUG:** Placebo
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02928029
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-10
- **Primary completion:** 2019-03-20
- **Final completion:** 2019-03-20
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Due to the changes of standard of care and the slow recruitment of participants.
- **Last updated:** 2020-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02928029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02928029, "Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02928029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*